Newron Pharmaceuticals Company Profile - aVenture Research
Newron Pharmaceuticals
Newron Pharmaceuticals develops nervous system therapies as a biopharmaceutical company and commercializes Xadago, a Parkinson's disease treatment, with pharmaceutical partners.
Newron Pharmaceuticals is a biopharmaceutical company whose business combines proprietary research and clinical development moving drug candidates from discovery to commercialization in central and peripheral nervous system diseases with the marketed Parkinson's disease treatment Xadago (safinamide), commercialized with pharmaceutical partners, and the development of evenamide. It partners non-core assets and in-licenses strategically relevant assets.
Evenamide, a glutamate modulator in clinical development as an add-on therapy for patients with treatment-resistant schizophrenia, has shown in clinical trial data improvements in efficacy measures alongside a favourable safety profile relative to currently available antipsychotic medications.